Home Online Features Neurizon's NUZ-001 Reduces Aggregation of Key ALS Disease Target TDP-43 in Preclinical Study
Neurizon’s NUZ-001 Reduces Aggregation of Key ALS Disease Target TDP-43 in Preclinical Study
Hand-out
Press Releases
November 19, 2024

Neurizon’s NUZ-001 Reduces Aggregation of Key ALS Disease Target TDP-43 in Preclinical Study

By Neurizon Therapeutics Limited

Highlights:

bradford

The Bradford Era

email
Local & Social